Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837413 | 1.00 | TAAR1 (0.46) | TAAR1IDO1TSHRCYP2A13LMNA | |
| SCHEMBL19385851 | 0.81 | ALDH1A1 (0.40) | TAAR1IDO1LMNAALDH1A1CA12 | |
| SCHEMBL12433152 | 0.80 | PARP10 (0.41) | TAAR1IDO1LMNAALDH1A1CA12 | |
| SCHEMBL2290496 | 0.74 | — | — | |
| SCHEMBL3386432 | 0.71 | IDO1 (0.50) | TAAR1IDO1TSHRLMNACYP1A2 | |
| SCHEMBL28957100 | 0.71 | TAAR1 (0.46) | TAAR1IDO1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL29181150 | 0.71 | HSPA5 (0.54) | TAAR1IDO1TSHRLMNACYP2D6 | |
| SCHEMBL778620 | 0.71 | TAAR1 (0.48) | TAAR1IDO1CYP2A13LMNACYP1A2 | |
| SCHEMBL776587 | 0.71 | TAAR1 (0.46) | TAAR1TSHRCYP2A13LMNAALDH1A1 | |
| SCHEMBL30837412 | 0.71 | TAAR1 (0.48) | TAAR1IDO1CYP2A13LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023171591-A1 | PRODUCTION METHOD FOR EPISULFIDE COMPOUND | 三菱瓦斯化学株式会社 | 2023-09-14 | — | — | WO | claimed |
| CN-104531397-A | Cleaning solution for sheet glass substrate thinning pre-cleaning, and application thereof | HUIJING DISPLAY TECHNOLOGY SUZHOU CO LTD | 2015-04-22 | — | — | CN | claimed |
| CN-117778339-A | Sulfoxide reductase mutant and application thereof in preparation of chiral sulfoxide and sulfinyl ester | 遵义医科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117757763-A | Sulfoxide reductase mutant and application thereof in chiral sulfoxide preparation | 遵义医科大学 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023171591-A1 | PRODUCTION METHOD FOR EPISULFIDE COMPOUND | 三菱瓦斯化学株式会社 | 2023-09-14 | — | — | WO | disclosed |
| CN-104531397-A | Cleaning solution for sheet glass substrate thinning pre-cleaning, and application thereof | HUIJING DISPLAY TECHNOLOGY SUZHOU CO LTD | 2015-04-22 | — | — | CN | disclosed |
| US-7776582-B2 | for gas chromatography; identifying an optically enhanced chiral ionic liquid (OCIL) for enantiomeric resolution | SIGMA-ALDRICH CO. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090145197-A1 | Optically Enhanced Chiral Ionic Liquids | SIGMA-ALDRICH CO. NEWCO INC. | 2009-06-11 | — | — | US | disclosed |
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | ADVANCED SEPARATION TECHNOLOGIES INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | GCG, INF2, ELOVL3 | TAAR1 1789/4885IDO1 737/4885TSHR 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.